|
| Study ID | Sample size (randomized/analyzed) | Participant age (years) | Duration of disease (years) | The differentiated patterns | (A) Treatment group intervention (n) | (B) Control group intervention (n) | Treatment duration/Follow-up duration | Main outcomes | Adverse events |
|
| Chen, 2019 | (A) 30/30
(B) 30/30 | (A) 40.62 ± 3.55
(B) 42.45 ± 3.64 | (A) 2.34 ± 0.25
(B) 2.62 ± 0.57 | None | Wet cupping | Diclofenac sodium | 3 months/none | 1. TER
2. Migraine attack frequency score
3. Migraine attack intensity score
4. Migraine attack intensity score
5. Headache duration time score
6. Headache intensity (VAS) | (A) 2 (dizziness 2)
(B) 9 (dizziness 1, abdominal pain 4, vomiting 2, nausea 2) |
| Jiang, 2015 | (A) 30/30
(B) 30/30 | (A)20–65
(B) 18–57 | (A) 0.5–16
(B) 2–13 | None | Wet cupping | Flunarizine | 4 weeks/none | 1. TER | NR |
| Song, 2013 | (A) 45/45
(B) 45/45 | (A) 35.4 ± 3.1
(B) 36.1 ± 2.3 | (A) 4.3 ± 2.2
(B) 3.5 ± 2.8 | Cold coagulation and blood stasis | Wet cupping | Flunarizine plus Ibuprofen (at acute attack) | 8 weeks/none | 1. TER
2. Headache intensity (VAS)
3. Migraine score | (A) 0
(B) 34 (fatigue 32, abdominal pain 2) |
| Jin, 2015 | (A) 35/35
(B) 35/35 | (A) 34 ± NR
(B) 33 ± NR | (A) 7.24 ± NR
(B) 6.81 ± NR | None | Dry cupping plus acupuncture | Acupuncture | 8 weeks/none | 1. TER
2. Headache intensity (VAS) | NR |
| Li, 2012 | (A) 50/50
(B) 50/50 | (A) 36.5 ± NR
(B)31.2 ± NR | (A) 9.2 ± NR
(B)8.7 ± NR | None | Dry cupping plus acupuncture | Acupuncture | 15 days/none | 1. TER
2. The number of days the headache has completely disappeared | NR |
| Zhang, 2020 | (A) 65/65
(B) 65/65 | 18–45 | >1 | None | Rizatriptan benzoate plus wet cupping | Rizatriptan benzoate | 20 days | 1. TER
2. 24hMQOLQ 3. Headache intensity (VAS) | NR |
|
